Dementia consortium. the dementia consortium is a partnership between alzheimer’s research uk, world leading pharmaceutical companies and partner contract research organisations. the initiative teams up leading researchers in universities across the world with uk based drug discovery experts to develop their research findings into new treatments. The dementia consortium is a charity industry partnership between alzheimer’s research uk and world leading pharmaceutical companies that bring together a collective expertise in dementia to co fund research projects of common interest. with industry partner support, research projects funded by the dementia consortium aim to validate novel.
Alzheimer’s research uk oversee all dementia consortium projects from confirming academic research findings in feasibility studies through to target validation and tool molecule generation studies. validated targets may be moved towards future pre clinical and clinical studies with the potential for licencing to industry partners and revenue. We need see many more trials taking place to help us put new treatments into the hands of people with dementia. alzheimer’s research uk’s newly announced drug discovery institute and dementia consortium will bring together the expertise needed to translate the best discoveries from academic research through to benefits for patients sooner. The dementia consortium that partners between aruk and 7 industry partners and 2 cros has accelerated dementia target validation and drug discovery for the development of new treatments. 1 founding charity providing access to the best translational research into dementia worldwide. The dementia consortium is a global initiative that sees alzheimer’s research uk partner with the pharmaceutical industry to validate novel targets for the diseases that cause dementia. the dementia consortium is seeking innovative academic proposals, which aim to robustly demonstrate target relevance to human disease. targets should have.
Comments are closed.